President and Executive Chairman
Vince Ippolito is President and Executive Chairman of Botanix Pharmaceuticals and responsible for the Company’s commercial operations worldwide. Mr Ippolito is based in Phoenix USA, where Botanix is building its commercial operations functions. Mr Ippolito also currently sits on the Board of Suneva Medical, a privately held regenerative aesthetics company. Mr Ippolito is a leading pharmaceutical expert who has over 30 years of experience in the industry, including more than 20 years in dermatology.
Throughout his career, he has launched more than 20 brands in dermatology and aesthetic medicine and played a leading role in two of the largest dermatology acquisitions completed in the past decade with combined valuations of $7.8 billion. He served as the Chief Commercial Officer Executive Vice President of Anacor Pharmaceuticals, a dermatology based biopharmaceutical company, until September 2017, where he was responsible for developing marketing and sales functions, as well as strategising the company’s product portfolio. Previously, Mr. Ippolito was Executive Vice President and Chief Commercial Officer at Medicis, an industry leading dermatology and aesthetic company.
Mr Matt Callahan is the founding executive director of Botanix. Matt is an experienced life sciences and health tech executive based in Philadelphia, USA. He has been the founding CEO or Executive Director of a number of pharmaceutical and health tech companies including iCeutica Inc, Churchill Pharma Inc. Dimerix Biosciences, Emerald Clinics and Orthocell. He has led the development of four products that have received FDA approval and he has more than 25 years legal, IP and investment management experience. Mr Callahan has worked as an investment director for two venture capital firms investing in lifesciences, technology and other sectors, and was general manager of Australian listed technology and licensing company ipernica (now Nearmap ASX:NEA), where he was responsible for the licensing programs that generated more than $120M in revenue.
Dr Michael Thurn
Dr Michael Thurn is an experienced senior executive with managerial and Board experience spanning 15 years. He has a background in drug regulation and biopharmaceutical industries, including senior roles in listed and private companies. Michael has worked extensively with life science start-ups across a range of technology platforms and has experience in drug discovery, preclinical and clinical development. He has guided and advised on the development of a range of NCEs (New Chemical Entities) through clinical trials, and possesses strong project management skills with a proven ability to raise capital.
Prior to Botanix Pharmaceuticals, Michael held managerial and executive roles at Mimetica, Spinifex Pharmaceuticals and Cytopia and was a toxicology reviewer with the Drug Safety and Evaluation Branch of the Therapeutic Goods Administration. Michael has a doctor of philosophy from University of Technology Sydney and was a Postdoctoral Research fellow at the Australian Institute of Marine Science.
Dr Stewart Washer
Dr Stewart Washer is a respected senior executive with more than 20 years of experience at Board and senior executive levels across medical technology, biotechnology and agrifood companies. He has an established track record and has overseen acquisitions and strategic partnerships in the pharmaceutical and cannabinoid medicine sectors, with some of the world’s leading companies. Dr Washer is currently active as an ASX board member with Orthocell (ASX:OCC), Zelda Therapeutics (ASX:ZLD) and Cynata Therapeutics (ASX:CYP). Previously, Dr Washer has been an Investment Director at Bioscience Managers, a leading life science investment firm and was a Venture Partner with the Swiss Inventages Fund, a €1.5bn life science fund, funded by Nestle. Dr Washer has held a number of Board positions previously including Chairman of Hatchtech which sold for A$279m in 2015 and as a Director of iCeutica, which was sold to US-based Iroko Pharmaceuticals in 2011.
Dr Bill Bosch
Chief Scientific Officer and Executive Director
Dr Bill Bosch is a seasoned pharmaceutical executive with more than 20 years of experience in the industry, focusing on applications of nanotechnology to drug product development. Dr Bosch worked with iCeutica Inc. as Chief Scientific Officer and is co-inventor of the SoluMatrix™ drug delivery technology, and has been instrumental in the development and scale up of the platform and development of three FDA approved products that use the SoluMatrix™ technology.
Before iCeutica, he was Director of Pharmaceutical Research at Elan Corporation where he managed the development activities for four commercial products which incorporate nanotechnology. Dr Bosch was a co-founder of NanoSystems LLC in 1995 and a co-inventor of NanoCrystal® Technology.
Dr Ron Dolle
CMC and Medicinal Chemistry
Dr Ron Dolle is an accomplished drug discovery executive with a record of innovation and success in drug design, team leadership, candidate selection, preclinical development, and registration. He also holds a Associate Professorship in the Department of Biochemistry and Molecular Biophysics at the Center for Drug discovery at the University of Washington in St Louis.
Dr Dolle is an expert in small molecule drug design, and has led cross-functional R&D teams at Cubist and Adolor in traditional and fully virtual research environments generating 16 development candidates including seven INDs. Dr Dolle’s research and management experience, honed in the pharmaceutical and biotech industries, spans the therapeutic areas of infectious disease, inflammation, gastrointestinal disorders, and CNS conditions (pain, affective, neurology).
Dr Joyce Rico
MD, MBA, FAAD
Dr Joyce Rico, is a board-certified dermatologist and recently served as the Chief Medical Officer of Novan Therapeutics Inc. Prior to joining Novan, Dr Rico served as Vice-President for Medical Affairs and Medical Science at Astellas Pharma. She has served on the faculty at Duke University, New York University, Northwestern University and the University of Miami. She received her MD from the University of Florida, her MBA from DePaul University, and completed her Dermatology residency at the University of Miami.
Dr Ira Lawrence
Dr Lawrence has over 30 years of senior level leadership experience within the global pharmaceutical and medical device industries. He currently serves as a senior‐level consultant, with numerous clients worldwide. Previously, he has served as the Chief Medical Officer of Alphaeon Corporation; Senior Vice President and Chief Medical Officer at Medicis Pharmaceutical Corporation; President and Chief Executive Officer and Member of the Board of Directors at SciClone Pharmaceuticals, Inc.; Senior Vice President of Research and Development at Astellas Pharmaceutical Company and Fujisawa Healthcare; and Senior Vice President of Research and Development at GenDerm Corporation. Dr Lawrence has had significant experience in the development and launch of numerous pharmaceuticals and devices and has played significant roles in over 75 INDs and IDEs, as well as, 17 NDAs, BLAs and PMAs. He is a Fellow of the American College of Physicians and has received numerous awards and honors. He is a member of several scientific and medical professional societies; the author of numerous scientific publications and textbooks; and has presented at several national and international scientific and medical meetings on a variety of subjects.